TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7751430

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg and Hydrochlorothiazide 6.25 mg (B5/H6.25)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bisoprolol 5 mg (B5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg (H25)
Number of subjects: 0
Study: 2340838

Group type: EXPERIMENTAL
Intervention: Sinemet-controlled release (CR4) 50 mg carbidopa/200 mg levodopa
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sinemet 25/100
Number of subjects: 24
Study: 881095

Group type: EXPERIMENTAL
Intervention: Sotalol hydrochloride
Number of subjects: 38

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 38
Study: 30565745

Group type: EXPERIMENTAL
Intervention: Probiotics and lactoferrin (2 capsules/day for 5 days followed by 1 capsule/day for additional 10 days, then 1 capsule/day for 10 consecutive days each month for 6 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (2 capsules/day for 5 days followed by 1 capsule/day for additional 10 days, then 1 capsule/day for 10 consecutive days each month for 6 months)
Number of subjects: 48
Study: 29202767

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 12.5 μg BID
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 25 μg BID
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 50 μg BID
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 μg BID
Number of subjects: 378
Study: 26338699

Group type: EXPERIMENTAL
Intervention: HIGH (300 min/week) aerobic exercise
Number of subjects: 400

Group type: COMPARATOR
Intervention: MODERATE (150 min/week) aerobic exercise
Number of subjects: 400
Study: 23553637

Group type: EXPERIMENTAL
Intervention: Quetiapine (QTP)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Risperidone (RIS)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Aripiprazole (ARP)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) in female participants
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) in male participants
Number of subjects: 222
Study: 16953529

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg intravenous morphine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 15364136

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT) with cisplatin and vinorelbine; cisplatin 80 mg/m² on day 1, vinorelbine 25 mg/m² on days 1 and 4 of cycles 1 and 4, and 12.5 mg/m² during cycles 2 and 3; RT started on day 4 of cycle 2.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sequential chemoradiotherapy (CRT) with cisplatin and vinorelbine; same chemotherapy regimen as concurrent arm; RT started within 2 weeks after completion of chemotherapy.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Concurrent CRT
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sequential CRT
Number of subjects: 102
Study: 10714910

Group type: EXPERIMENTAL
Intervention: Micronised 17beta oestradiol (2 mg daily) + dydrogesterone (5-20 mg for last 14 days)
Number of subjects: 271
Study: 9013370

Group type: EXPERIMENTAL
Intervention: Anabolic steroids
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (nonusers)
Number of subjects: 24
Study: 1731540

Group type: EXPERIMENTAL
Intervention: 1000 mL of 5% dextrose + 1000 mL of Ringers solution (RS) + 250 mL of 5% human albumin (HA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1750 mL of RS + 500 mL of 3.5% gelatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1850 mL of RS + 400 mL of 20% HA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1750 mL of RS + 500 mL of 10% low molecular weight hydroxyethyl starch
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2250 mL of RS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 60
Study: 3891584

Group type: EXPERIMENTAL
Intervention: Triple tetracycline or erythromycin stearate (two week course)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 113
Study: 31747825

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA injections combined with upper-limb physiotherapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo injections combined with upper-limb physiotherapy
Number of subjects: 28
Study: 30626439

Group type: EXPERIMENTAL
Intervention: Brief telephone counselling intervention (3 phone calls focused on stress reduction and self-management strategies)
Number of subjects: 359
Study: 27888473

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol acetate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Gomenol oil
Number of subjects: 32
Study: 26099918

Group type: EXPERIMENTAL
Intervention: Distraction Osteogenesis (DO)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Bilateral Sagittal Split Osteotomy (BSSO)
Number of subjects: 66
Study: 24780350

Group type: EXPERIMENTAL
Intervention: 3D titanium miniplate and screws
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard titanium miniplates and screws
Number of subjects: 30
Study: 22465175

Group type: EXPERIMENTAL
Intervention: Potassium-sparing diuretics (N = 192)
Number of subjects: 3069

Group type: COMPARATOR
Intervention: ACE‐I or AT2RB
Number of subjects: 3069
Study: 19307987

Group type: COMPARATOR
Intervention: Medication-only condition
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Medication and behavioral treatment
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Physiological adherence measures via saliva assays
Number of subjects: 254

Group type: COMPARATOR
Intervention: Parent report of medication adherence
Number of subjects: 254
Study: 17710011

Group type: EXPERIMENTAL
Intervention: High dose remifentanil (0.4 microg/kg/min)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low dose remifentanil (0.1 microg/kg/min)
Number of subjects: 42
Study: 15140851

Group type: EXPERIMENTAL
Intervention: OA Knee programme
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: OA Hip programme
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 11558855

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0

Group type: COMPARATOR
Intervention: GP IIb/IIIa-receptor inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tirofiban and Abciximab
Number of subjects: 0
Study: 9678793

Group type: EXPERIMENTAL
Intervention: Stem cell factor (SCF) 20 microg/kg plus G‐CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: G‐CSF alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCF 20 microg/kg plus G‐CSF 5 microg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCF administration
Number of subjects: 0
Study: 8205878

Group type: EXPERIMENTAL
Intervention: IPV with 2.5 mg albuterol (internal percussive component activated)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IPV with 2.5 mg albuterol (internal percussive component inactivated) followed by P&PD
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nebulizer with 2.5 mg albuterol followed by P&PD
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IPV
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 9
Study: 2913847

Group type: EXPERIMENTAL
Intervention: Prophylactic transdermal scopolamine patches
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 32
Study: 30698839

Group type: EXPERIMENTAL
Intervention: Prazosin (16 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 28704377

Group type: EXPERIMENTAL
Intervention: Team Coaching Concept (TCC)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 305
Study: 25498847

Group type: EXPERIMENTAL
Intervention: Indoor residual spraying with dichlorodiphenyltrichloroethane plus LLINs
Number of subjects: 7845

Group type: COMPARATOR
Intervention: LLINs alone
Number of subjects: 7845
Study: 22302453

Group type: EXPERIMENTAL
Intervention: Comprehensive periodontal treatment during pregnancy
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group (one session of supragingival scaling and oral hygiene instruction after delivery)
Number of subjects: 303
Study: 21777233

Group type: EXPERIMENTAL
Intervention: Albendazole plus antiepileptics
Number of subjects: 123

Group type: COMPARATOR
Intervention: Antiepileptics only
Number of subjects: 123
Study: 19343018

Group type: EXPERIMENTAL
Intervention: Internet group (n = 34)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (information only, n = 31)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Internet group (compliers)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Internet group (noncompliers)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 16946304

Group type: EXPERIMENTAL
Intervention: R-maintenance after R-FCM
Number of subjects: 176

Group type: COMPARATOR
Intervention: R-FCM
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: R-maintenance after R-FCM in FL
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: R-maintenance after R-FCM in MCL
Number of subjects: 176
Study: 15651177

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caspofungin (echinocandin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid formulation of amphotericin B or echinocandin
Number of subjects: 0
Study: 11294164

Group type: EXPERIMENTAL
Intervention: Angry participants
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Grateful participants
Number of subjects: 229

Group type: COMPARATOR
Intervention: Sad participants
Number of subjects: 229

Group type: COMPARATOR
Intervention: Happy participants
Number of subjects: 229
Study: 9431533

Group type: EXPERIMENTAL
Intervention: 5% acyclovir cream
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 196
Study: 8290742

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 31013539

Group type: EXPERIMENTAL
Intervention: Early Premature Infant Oral Motor Intervention (PIOMI), given 15 to 30 minutes before feeding once a day for 14 days
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Early Premature Infant Oral Motor Intervention (PIOMI)
Number of subjects: 151
Study: 28712955

Group type: EXPERIMENTAL
Intervention: Increasing right ventricular stroke work index (RVSWI)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Increasing left ventricular stroke work index (LVSWI)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: ΔRVSWI ≤1.07 mm Hg⋅L⋅m-2 and ΔLVSWI ≤4.57 mm Hg⋅L⋅m-2
Number of subjects: 175
Study: 26033416

Group type: EXPERIMENTAL
Intervention: Parenteral oestrogen
Number of subjects: 915

Group type: COMPARATOR
Intervention: Total androgen blockade
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: EORTC-C30 ratings
Number of subjects: 915
Study: 25528363

Group type: EXPERIMENTAL
Intervention: FGF-23 levels above the median (395 RU/mL)
Number of subjects: 600

Group type: COMPARATOR
Intervention: FGF-23 levels below the median
Number of subjects: 600
Study: 22459731

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 15
Study: 20547698

Group type: EXPERIMENTAL
Intervention: Online questionnaire
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Postal questionnaire
Number of subjects: 1329
Study: 18727823

Group type: EXPERIMENTAL
Intervention: Personalized feedback pamphlet condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control pamphlet condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention control condition
Number of subjects: 0
Study: 15836716

Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d., amoxicillin 1 g b.d., and clarithromycin 500 mg b.d. (RAC group, n = 28)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d., metronidazole 500 mg b.d., and tetracycline 500 mg b.d. (RMT group, n = 28)
Number of subjects: 116

Group type: COMPARATOR
Intervention: First-line Maastricht therapy
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: RAC group
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: RMT group
Number of subjects: 116
Study: 12053583

Group type: EXPERIMENTAL
Intervention: LPS-stimulated T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-stimulated T cell cultures with added monocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPS-stimulated T lymphocytes with added monocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-atopic asthma patients)
Number of subjects: 0
Study: 10986030

Group type: EXPERIMENTAL
Intervention: Topical autologous platelet lysate applied twice per week for up to 9 months in combination with standardised compression bandaging
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo buffer solution applied twice per week for up to 9 months in combination with standardised compression bandaging
Number of subjects: 86
Study: 8674804

Group type: EXPERIMENTAL
Intervention: roxatidine
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: famotidine
Number of subjects: 339

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 339
Study: 1944755

Group type: EXPERIMENTAL
Intervention: Ciclosporin and low-dose prednisone
Number of subjects: 28

Group type: COMPARATOR
Intervention: High-dose prednisone
Number of subjects: 28
Study: 6864445

Group type: EXPERIMENTAL
Intervention: Experimental group (exposed to two treatments designed to reduce imitation of aggressive behaviors)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (received comparable neutral treatments)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 169
Study: 31419080

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA) 1 g
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study: 29196478

Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Clinical hypnotherapy (HT)
Number of subjects: 160
Study: 25274048

Group type: EXPERIMENTAL
Intervention: Directive risk-based strategy
Number of subjects: 1483

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 1483
Study: 23835709

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) - take-home booklet
Number of subjects: 276

Group type: COMPARATOR
Intervention: Standard information booklet (control condition)
Number of subjects: 276
Study: 22131203

Group type: EXPERIMENTAL
Intervention: Creatine (Cr, di‐creatine citrate; n=27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (PL; n=28)
Number of subjects: 55
Study: 19318634

Group type: EXPERIMENTAL
Intervention: Factor D (50 microg selenium, 30 mg vitamin E, and 15 mg beta-carotene)
Number of subjects: 29584

Group type: EXPERIMENTAL
Intervention: Factor D
Number of subjects: 29584
Study: 16980004

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 80
Study: 11995457

Group type: EXPERIMENTAL
Intervention: IL-2 preoperative immunotherapy (12 million IU/day subcutaneously for 3 consecutive days prior to surgery)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IL-2 preoperative immunotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 30
Study: 10431942

Group type: EXPERIMENTAL
Intervention: 250 mg of caffeine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 125 mg of caffeine
Number of subjects: 62

Group type: COMPARATOR
Intervention: 0 mg of caffeine (placebo)
Number of subjects: 62
Study: 8549887

Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge (DBPCFC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diet history
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: General Health Questionnaire assessment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Individually based diet after 3-4 months
Number of subjects: 17
Study: 2124540

Group type: EXPERIMENTAL
Intervention: Protriptyline
Number of subjects: 18
Study: 582360

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 6628517

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily
Number of subjects: 8
Study: 30777122

Group type: EXPERIMENTAL
Intervention: Consult for Addiction Treatment and Care in Hospitals (CATCH) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 28719977

Group type: EXPERIMENTAL
Intervention: Interactive, motion capture rehabilitation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual care stroke rehabilitation
Number of subjects: 73
Study: 25343955

Group type: EXPERIMENTAL
Intervention: Aryoseven (90 to 120 μg/kg intravenously every 2 hours)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Novoseven (90 to 120 μg/kg intravenously every 2 hours)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Aryoseven
Number of subjects: 66

Group type: COMPARATOR
Intervention: Novoseven
Number of subjects: 66
Study: 24509688

Group type: EXPERIMENTAL
Intervention: His or para-His pacing (HP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Right ventricular septal pacing (RVSP)
Number of subjects: 38
Study: 22780962

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 20112413

Group type: EXPERIMENTAL
Intervention: Oral propranolol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Adjuvant therapy (laser therapy, steroid injections) for partial and nonresponders
Number of subjects: 32
Study: 18021468

Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan at 0.4 mCi/kg (for patients <= 80 kg)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan at 32 mCi (for patients > 80 kg)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan (both groups)
Number of subjects: 170
Study: 16241925

Group type: EXPERIMENTAL
Intervention: Higher adherence to the Mediterranean diet (10-unit increase in diet score)
Number of subjects: 3042

Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 3042
Study: 12435698

Group type: EXPERIMENTAL
Intervention: Intravenous ARS (2.4 mg/kg) followed by intramuscular ARS (1.2 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intramuscular ARS (2.4 mg/kg) followed by intravenous ARS (1.2 mg/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intramuscular ARS
Number of subjects: 28
Study: 10521548

Group type: EXPERIMENTAL
Intervention: Small hematoma (transaxial size ≤20 mm)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Initial level of consciousness
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Transaxial size of the hematoma on CT
Number of subjects: 80
Study: 7892818

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 892
Study: 1955508

Group type: EXPERIMENTAL
Intervention: recombinant human GH (hGH) 3 IU (1.25 mg)/m2.day, administered via sc injections 6 days/week, either in the morning or in the evening for 12 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: recombinant human GH (hGH) 3 IU (1.25 mg)/m2.day, administered via sc injections 6 days/week
Number of subjects: 40
Study: 6791491

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition regimen adequate in amino acids and glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semistarved adult patients with upper gastrointestinal tract malignancies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal healthy adult controls
Number of subjects: 0
Study: 30720379

Group type: EXPERIMENTAL
Intervention: Prenatal counseling sessions (4 sessions in the third trimester)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 108
Study: 30728043

Group type: EXPERIMENTAL
Intervention: Practice-specific antibiotic-prescription feedback and educational outreach visit, including e-learning modules and tablet PCs with information on antibiotics.
Number of subjects: 114

Group type: COMPARATOR
Intervention: Care as usual (Control group).
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Narrow-spectrum antibiotics.
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics.
Number of subjects: 114
Study: 30024805

Group type: EXPERIMENTAL
Intervention: Community health worker intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study: 27342514

Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: No hydroxyurea therapy
Number of subjects: 29
Study: 25189626

Group type: EXPERIMENTAL
Intervention: Invasive treatment (coronary angiography and intervention if feasible)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 200
Study: 22324977

Group type: EXPERIMENTAL
Intervention: Chest radiographic scoring system
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Chest radiographic scoring system (excluding atelectasis)
Number of subjects: 84
Study: 19149822

Group type: EXPERIMENTAL
Intervention: 7-day taper
Number of subjects: 516

Group type: COMPARATOR
Intervention: 28-day taper
Number of subjects: 516
Study: 17224697

Group type: EXPERIMENTAL
Intervention: HeartCare - home support program for patients after coronary artery bypass graft surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E‐CHANGE - Internet‐based home support program designed to increase lifestyle exercise after a cardiac event
Number of subjects: 0
Study: 15786530

Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline
Number of subjects: 52
Study: 12398954

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1587

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1587
Study: 9857602

Group type: EXPERIMENTAL
Intervention: Sentalloy (superelastic nickel‐titanium alloy, 0.014 inch)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Nitinol (conventional nickel‐titanium aligning archwire, 0.014 inch)
Number of subjects: 128